From: Inadequate reporting quality of registered genome editing trials: an observational study
WHO ICTRP targets | No. (%) of trials |
---|---|
Single target | |
BCL11A gene | 5 (6.2) |
CCR5 gene | 10 (12.3) |
CEP290 gene | 1 (1.2) |
CISH gene | 2 (2.5) |
Factor IX gene | 2 (2.5) |
HBB gene | 1 (1.2) |
HPV oncogenes E6 or E7 | 3 (3.7) |
IDS gene | 1 (1.2) |
IDUA gene | 1 (1.2) |
PDCD1 gene | 15 (18.5) |
CAR T cells therapy targets: | 23 (28.4) |
BCMA | 3 (3.7) |
CD7 | 2 (2.5) |
CD19 | 12 (14.8) |
CD22 | 1 (1.2) |
CD70 | 2 (2.5) |
CD123 | 2 (2.5) |
CS1 | 1 (1.2) |
Multiple targets | |
PDCD1, NY-ESO-1, TRAC | 1 (1.2) |
PDCD1, mesothelin (CARTs) | 2 (2.5) |
PDCD1, CD19 (CARTs) | 2 (2.5) |
PDCD1, MUC1 (CARTs) | 3 (3.7) |
CCR5, CD4 (CARTs) | 1 (1.2) |
CD19 and CD20/CD22 (CARTs) | 1 (1.2) |
CD19 and HPK1 (CARTs) | 1 (1.2) |
CD19, CD52, TRAC (CARTs) | 1 (1.2) |
CD19, B2M, TRAC (CARTs) | 1 (1.2) |
IL13 zetakine/HyTk (CARTs) | 1 (1.2) |
CD7 and CD28 (CARTs) | 1 (1.2) |
Not stated | 2 (2.5) |